Manerix

Moclobemide, the active ingredient in Manerix, is a monoamine oxidase inhibitor presented as an oral tablet for oral use. It treats major depressive disorder and dysthymia in adult patients. Manerix is marketed in the European Union and follows EU regulatory standards for quality and safety.

GNH USA supplies Manerix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manerix, a reversible MAO‑A inhibitor, is indicated for depressive disorders and related conditions.

- Major depressive disorder: alleviates depressive symptoms and improves functional outcomes in adults. - Dysthymia: reduces persistent low‑grade depressive mood over long periods. - Depressive disorder (broad): provides symptomatic relief in various depressive presentations when other agents are unsuitable.

Moclobemide may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and rare events.

Common Side Effects: - Nausea - Headache - Insomnia or somnolence - Dizziness - Dry mouth - Mild hypertension

Serious or Rare Side Effects: - Hypertensive crisis, especially with tyramine‑rich foods - Serotonin syndrome when combined with serotonergic agents - Severe liver injury - Agranulocytosis - Psychosis or severe mood destabilisation

Before initiating Manerix, several safety considerations are recommended.

- Assess hepatic function: evaluate liver enzymes prior to treatment. - Monitor blood pressure: watch for hypertensive reactions, especially after dietary tyramine intake. - Avoid tyramine‑rich foods: reduce risk of hypertensive crisis. - Review concomitant serotonergic drugs: prevent serotonin syndrome. - Pregnancy category B: use only when potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Moclobemide interacts with several drug classes; some combinations must be avoided, while others require careful monitoring.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Serotonin‑norepinephrine reuptake inhibitors (SNRIs). - Meperidine and other opioid analgesics. - St. John's wort (hypericum perforatum). - Sympathomimetic agents (e.g., pseudoephedrine).

Moderate Interactions (Monitor Closely): - Antihypertensives: may potentiate hypotensive effects. - Anticholinergic drugs: increased anticholinergic burden. - Cimetidine: may raise moclobemide plasma levels. - Carbamazepine: may reduce moclobemide efficacy. - Alcohol: can enhance central nervous system depression.